|
AU527784B2
(en)
|
1978-05-26 |
1983-03-24 |
Bang, Hans Olaf Dr. |
Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
|
|
US4377526A
(en)
|
1981-05-15 |
1983-03-22 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid and its esters
|
|
CA1239587A
(en)
|
1983-10-24 |
1988-07-26 |
David Rubin |
Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
|
|
US4526902A
(en)
|
1983-10-24 |
1985-07-02 |
Century Laboratories, Inc. |
Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
|
|
JPS6135356A
(ja)
|
1984-07-27 |
1986-02-19 |
Nippon Oil & Fats Co Ltd |
血液脂質脂肪酸の分析方法
|
|
EP0347509A1
(en)
|
1988-06-21 |
1989-12-27 |
Century Laboratories Inc. |
A process of extraction and purification of polyunsaturated fatty acids from natural sources
|
|
US4920098A
(en)
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
|
EP0273708B1
(en)
|
1986-12-26 |
1994-03-23 |
Sagami Chemical Research Center |
Process for production of eicosapentaenoic acid
|
|
JPS63185390A
(ja)
|
1987-01-27 |
1988-07-30 |
Suntory Ltd |
藻類によるエイコサペンタエン酸の製造方法
|
|
US5252333A
(en)
|
1987-04-27 |
1993-10-12 |
Scotia Holdings Plc |
Lithium salt-containing pharmaceutical compositions
|
|
US5198468A
(en)
|
1987-06-24 |
1993-03-30 |
Efamol Holdings Plc |
Essential fatty acid composition
|
|
US4843095A
(en)
|
1987-08-07 |
1989-06-27 |
Century Laboratories, Inc. |
Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
|
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
|
US5116871A
(en)
|
1988-09-13 |
1992-05-26 |
Efamol Holdings Plc |
Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
|
|
GB2223943A
(en)
|
1988-10-21 |
1990-04-25 |
Tillotts Pharma Ag |
Oral disage forms of omega-3 polyunsaturated acids
|
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
|
JP2839276B2
(ja)
|
1989-01-23 |
1998-12-16 |
日本分光工業株式会社 |
超臨界流体抽出・分離方法及び装置
|
|
US5457130A
(en)
|
1989-03-20 |
1995-10-10 |
Cancer Research Campaign Technology Limited |
Eicosapentaenoic acid used to treat cachexia
|
|
GB8906369D0
(en)
|
1989-03-20 |
1989-05-04 |
Tisdale Michael J |
Eicosapentaenoic acid
|
|
CA2043615C
(en)
|
1990-06-04 |
2001-08-14 |
Kazuhiko Hata |
Method of producing eicosapentaenoic acid or the ester derivative thereof
|
|
GB9012651D0
(en)
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
|
JP3103588B2
(ja)
|
1990-11-16 |
2000-10-30 |
持田製薬株式会社 |
リポプロテイン（ａ）低下剤
|
|
SE9101642D0
(sv)
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
|
US5215630A
(en)
|
1991-06-04 |
1993-06-01 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
|
|
WO1993003450A1
(en)
|
1991-07-30 |
1993-02-18 |
North Carolina State University |
Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
|
|
DE4133694C2
(de)
|
1991-10-11 |
1993-10-07 |
Fresenius Ag |
Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
|
|
JP3400466B2
(ja)
|
1991-10-28 |
2003-04-28 |
日本水産株式会社 |
高純度エイコサペンタエン酸またはそのエステルの製造方法
|
|
JPH0649479A
(ja)
|
1992-07-28 |
1994-02-22 |
Maruha Corp |
ω−３不飽和脂肪酸系化合物の安定化法
|
|
US5888541A
(en)
|
1992-08-21 |
1999-03-30 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
GB9217780D0
(en)
|
1992-08-21 |
1992-10-07 |
Efamol Holdings |
Fatty acid treatment
|
|
JPH0692847A
(ja)
|
1992-09-11 |
1994-04-05 |
Mochida Pharmaceut Co Ltd |
骨粗鬆症治療剤
|
|
GB9300125D0
(en)
|
1993-01-06 |
1993-03-03 |
Scotia Holdings Plc |
Compositions containing esters of unsaturated fatty acids
|
|
AU7053494A
(en)
|
1993-06-04 |
1995-01-03 |
Martek Biosciences Corporation |
Method of treating coronary vascular disease using docosahexaenoic acid
|
|
GB9318611D0
(en)
|
1993-09-08 |
1993-10-27 |
Sandoz Nutrition Ltd |
Improvements in or relating to organic compounds
|
|
JP3325995B2
(ja)
|
1994-02-28 |
2002-09-17 |
ミサワホーム株式会社 |
パネル接合構造
|
|
GB9403857D0
(en)
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
|
GB9404483D0
(en)
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
|
US5385929A
(en)
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
|
US5760081A
(en)
|
1994-05-10 |
1998-06-02 |
The General Hospital Corporation |
Omega 3 fatty acids in the prevention of ventricular fibrillation
|
|
JP3368100B2
(ja)
|
1994-06-02 |
2003-01-20 |
キヤノン株式会社 |
静電荷像現像用トナー
|
|
AU711482B2
(en)
|
1994-06-28 |
1999-10-14 |
Scotia Holdings Plc |
Compositions for treatment of diabetic complications
|
|
IT1274734B
(it)
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
|
JP2780154B2
(ja)
|
1995-02-17 |
1998-07-30 |
株式会社ヤクルト本社 |
ヨーグルト
|
|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
|
GB9509764D0
(en)
|
1995-05-15 |
1995-07-05 |
Tillotts Pharma Ag |
Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
|
|
JPH0959206A
(ja)
|
1995-08-25 |
1997-03-04 |
Nippon Oil & Fats Co Ltd |
エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
|
|
GB9519661D0
(en)
|
1995-09-27 |
1995-11-29 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
US5763496A
(en)
|
1995-11-27 |
1998-06-09 |
The Research Foundation Of State University Of New York |
Prevention of atherosclerosis using NADPH oxidase inhibitors
|
|
AU2738497A
(en)
|
1996-04-24 |
1997-11-12 |
Brigham And Women's Hospital |
Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
|
|
US6077828A
(en)
|
1996-04-25 |
2000-06-20 |
Abbott Laboratories |
Method for the prevention and treatment of cachexia and anorexia
|
|
US6248398B1
(en)
|
1996-05-22 |
2001-06-19 |
Applied Materials, Inc. |
Coater having a controllable pressurized process chamber for semiconductor processing
|
|
TW425285B
(en)
|
1996-06-10 |
2001-03-11 |
Viva America Marketing Inc |
Fish oil and garlic nutritive supplement
|
|
US5861399A
(en)
|
1996-07-17 |
1999-01-19 |
Heart Care Partners |
Methods and compositions for the rapid and enduring relief of inadequate myocardial function
|
|
US20020055539A1
(en)
|
1996-10-02 |
2002-05-09 |
Bockow Barry I. |
Compositions and methods for treating cardiovascular conditions
|
|
WO1998016216A1
(en)
|
1996-10-11 |
1998-04-23 |
Scotia Holdings Plc |
Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
|
|
ES2179156T3
(es)
|
1996-11-20 |
2003-01-16 |
Nutricia Nv |
Composicion nutricional que incluye grasas para el tratamiento del sindrome metabolico.
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
WO1999022719A1
(fr)
|
1997-10-30 |
1999-05-14 |
Morishita Jintan Co., Ltd. |
Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
|
|
US6362236B1
(en)
|
1997-11-25 |
2002-03-26 |
Warner-Lambert Company |
Inhibition of lipoprotein oxidation
|
|
JP4761093B2
(ja)
|
1997-12-10 |
2011-08-31 |
シクロスポリン セラポイティクス リミテッド |
オメガ−３脂肪酸油を含む医薬組成物
|
|
NZ500703A
(en)
|
1998-11-04 |
2001-06-29 |
F |
Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
|
|
US20020055529A1
(en)
|
1998-12-02 |
2002-05-09 |
Bisgaier Charles Larry |
Method for treating alzheimer's disease
|
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
|
CA2260397A1
(en)
|
1999-01-29 |
2000-07-29 |
Atlantis Marine Inc. |
Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
|
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
|
US6193999B1
(en)
|
1999-03-01 |
2001-02-27 |
Banner Pharmacaps, Inc. |
Gum acacia substituted soft gelatin capsules
|
|
WO2000051576A2
(en)
|
1999-03-03 |
2000-09-08 |
Ida Royalty Aps |
Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain
|
|
EP1166652B2
(en)
|
1999-03-04 |
2016-07-13 |
Suntory Holdings Limited |
Utilization of material containing docosapentaenoic acid
|
|
US20020054871A1
(en)
|
1999-04-12 |
2002-05-09 |
Yadong Huang |
Methods and compositions for use in the treatment of hyperlipidemia
|
|
US7112609B2
(en)
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
|
CA2311974A1
(en)
|
1999-06-28 |
2000-12-28 |
Nisshin Flour Milling Co., Ltd. |
Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
|
|
GB9916536D0
(en)
|
1999-07-14 |
1999-09-15 |
Scarista Limited |
Nutritional or pharmaceutical compositions
|
|
ATE394941T1
(de)
|
1999-07-28 |
2008-05-15 |
Swiss Caps Rechte & Lizenzen |
Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung
|
|
WO2001015552A1
(en)
|
1999-08-30 |
2001-03-08 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
|
JP4170542B2
(ja)
|
1999-11-18 |
2008-10-22 |
日油株式会社 |
高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
|
|
EP1125914A1
(en)
|
2000-02-14 |
2001-08-22 |
Nisshin Flour Milling Co., Ltd. |
Process for separating and purifying eicosapentaenoic acid or its ester
|
|
ATE305810T1
(de)
|
2000-05-22 |
2005-10-15 |
Pro Aparts Investimentos E Con |
Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
|
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
GB0016045D0
(en)
|
2000-06-29 |
2000-08-23 |
Laxdale Limited |
Therapeutic combinations of fatty acids
|
|
GB0016452D0
(en)
|
2000-07-04 |
2000-08-23 |
Kilgowan Limited |
Vitamin K and essential fatty acids
|
|
JP4391673B2
(ja)
|
2000-08-08 |
2009-12-24 |
花王株式会社 |
油脂組成物
|
|
CN1735416A
(zh)
|
2000-08-15 |
2006-02-15 |
辉瑞产品公司 |
治疗剂组合
|
|
GB0101198D0
(en)
|
2001-01-17 |
2001-02-28 |
Scherer Technologies Inc R P |
Ingestible compositions containing an odoriferous oil
|
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
|
GB0111282D0
(en)
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
|
RU2003133142A
(ru)
|
2001-05-30 |
2005-04-20 |
Лэксдейл Лимитед (GB) |
Коэнзим q и эйкозапентаеновая кислота (эпк)
|
|
US20120214771A1
(en)
|
2001-07-27 |
2012-08-23 |
Fontini Sampalis |
Compositions for treatment of cardiometabolic disorders
|
|
ITMI20012384A1
(it)
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
|
US20030144219A1
(en)
*
|
2001-11-15 |
2003-07-31 |
Phinney Stephen Dodge |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
|
ITMI20020269A1
(it)
|
2002-02-12 |
2003-08-12 |
Victorix Assets Ltd |
Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
|
|
JP2003306690A
(ja)
|
2002-02-18 |
2003-10-31 |
Nooburu:Kk |
多価不飽和脂肪酸含有油脂組成物
|
|
US20030166614A1
(en)
|
2002-03-01 |
2003-09-04 |
Harrison Stanley F. |
Method for reducing cholesterol and triglycerides
|
|
AU2003229993B2
(en)
|
2002-05-03 |
2008-07-24 |
Pronova Biopharma Norge As |
Use of EPA and DHA in secondary prevention
|
|
ES2524000T3
(es)
|
2002-06-05 |
2014-12-03 |
Teva Czech Industries S.R.O. |
Reducción de la reticulación de la gelatina
|
|
CA2390820A1
(en)
|
2002-06-17 |
2003-12-17 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
US20040001874A1
(en)
|
2002-06-24 |
2004-01-01 |
Vital Living, Inc. |
Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
|
|
WO2004004638A2
(en)
*
|
2002-07-02 |
2004-01-15 |
Galileo Pharmaceuticals, Inc. |
Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
|
|
US20060211761A1
(en)
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
EP1547588B1
(en)
|
2002-08-20 |
2013-12-11 |
Kowa Company, Ltd. |
Soft capsule preparation
|
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
US8017651B2
(en)
|
2002-11-22 |
2011-09-13 |
Bionexus, Ltd. |
Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
|
|
AU2003284633B2
(en)
|
2002-11-22 |
2008-07-10 |
Nippon Suisan Kaisha, Ltd. |
External composition containing polyunsaturated fatty acid or its salt or ester
|
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
|
US8124582B2
(en)
*
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
GB0301701D0
(en)
|
2003-01-24 |
2003-02-26 |
Ensay Ltd |
Psoriasis and Eicosapentaenoic acid
|
|
EP1587377A2
(en)
|
2003-01-31 |
2005-10-26 |
The Procter & Gamble Company |
Means for improving the appearance of mammalian keratinous tissue
|
|
CA2515293C
(en)
|
2003-02-07 |
2012-03-20 |
Mochida Pharmaceutical Co., Ltd. |
Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
|
|
CA2516333C
(en)
|
2003-02-21 |
2011-08-23 |
Mochida Pharmaceutical Co., Ltd. |
Drug for reducing side effects in ribavirin / interferon combination therapy
|
|
BRPI0408006A
(pt)
|
2003-03-05 |
2006-02-14 |
Solvay Pharm Gmbh |
uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos
|
|
AU2004222633B2
(en)
|
2003-03-18 |
2008-05-01 |
Nestec S.A. |
Compositions comprising fatty acids and amino acids
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
US6846942B2
(en)
|
2003-05-20 |
2005-01-25 |
David Rubin |
Method for preparing pure EPA and pure DHA
|
|
US7205329B2
(en)
|
2003-05-30 |
2007-04-17 |
Microbia, Inc. |
Modulators of CRTH2 activity
|
|
WO2004112777A1
(ja)
|
2003-06-20 |
2004-12-29 |
Mochida Pharmaceutical Co., Ltd. |
下肢静脈瘤予防・治療用組成物
|
|
WO2005020785A2
(en)
|
2003-07-15 |
2005-03-10 |
The Regents Of The University Of California |
Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
|
|
WO2005009412A1
(en)
|
2003-07-24 |
2005-02-03 |
Wockhardt Limited |
Oral compositions for treatment of diseases
|
|
CN101128475B
(zh)
|
2003-11-12 |
2012-06-20 |
纳幕尔杜邦公司 |
适用于改变产油植物及酵母中多不饱和脂肪酸水平的△15脂肪酸去饱和酶
|
|
ITMI20032247A1
(it)
|
2003-11-19 |
2005-05-20 |
Tiberio Bruzzese |
Interazione di derivati polari di composti insaturi con substrati inorganici
|
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
|
EP1711173A2
(en)
|
2003-12-31 |
2006-10-18 |
Igennus Limited |
Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
|
|
IL159729A0
(en)
|
2004-01-06 |
2004-06-20 |
Doron I Friedman |
Non-aqueous composition for oral delivery of insoluble bioactive agents
|
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
|
US7022713B2
(en)
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
|
EP1591114A1
(en)
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
|
US20050215640A1
(en)
|
2004-03-26 |
2005-09-29 |
Baxter Jeffrey H |
HMB compositions and uses thereof
|
|
US7923043B2
(en)
|
2004-03-30 |
2011-04-12 |
Theta Biomedical Consulting & Development Co., Inc. |
Method for protecting humans against superficial vasodilator flush syndrome
|
|
US20050244367A1
(en)
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
|
US20050272095A1
(en)
|
2004-05-19 |
2005-12-08 |
Ppd Biomarker Discovery Sciences, Llc |
Methods of identifying biomarkers
|
|
TW200613009A
(en)
|
2004-06-11 |
2006-05-01 |
Ono Pharmaceutical Co |
Capsule having chewing stability
|
|
GB0413729D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
|
GB0413730D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
|
ITRM20040395A1
(it)
|
2004-08-03 |
2004-11-03 |
Sigma Tau Ind Farmaceuti |
Composizione comprendente statine e acidi grassi omega 3.
|
|
US7642287B2
(en)
|
2004-08-06 |
2010-01-05 |
Transform Pharmaceuticals, Inc. |
Statin pharmaceutical compositions and related methods of treatment
|
|
US20090042979A1
(en)
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
|
WO2006017627A2
(en)
|
2004-08-06 |
2006-02-16 |
Barry Sears |
Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
|
|
JP4943849B2
(ja)
|
2004-08-18 |
2012-05-30 |
持田製薬株式会社 |
ゼリー組成物
|
|
US20060051418A1
(en)
|
2004-08-25 |
2006-03-09 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
|
CN1759834B
(zh)
*
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
|
EP2153824A1
(en)
|
2004-09-27 |
2010-02-17 |
Sigmoid Pharma Limited |
Seamless multiparticulate formulations
|
|
WO2006085144A2
(en)
*
|
2004-10-15 |
2006-08-17 |
Photonz Corporation Limited |
Compositions containing high omega-3 and low saturated fatty acid levels
|
|
FR2878747B1
(fr)
|
2004-12-03 |
2007-03-30 |
Pierre Fabre Medicament Sa |
Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
|
|
US20090239927A1
(en)
|
2004-12-06 |
2009-09-24 |
George Bobotas |
Statin and Omega-3 Fatty Acids For Lipid Therapy
|
|
US20070191467A1
(en)
|
2004-12-06 |
2007-08-16 |
Reliant Pharmaceutical, Inc. |
Statin and omega-3 fatty acids for lipid therapy
|
|
CN101098690A
(zh)
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
|
WO2006062748A2
(en)
|
2004-12-06 |
2006-06-15 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
|
|
US20060135610A1
(en)
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
|
GB2421909A
(en)
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
|
CA2593768C
(en)
|
2005-01-04 |
2014-02-18 |
Mochida Pharmaceutical Co., Ltd. |
Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
|
|
US20080200707A1
(en)
|
2005-01-04 |
2008-08-21 |
Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. |
Lipotoxicity Relieving Agent
|
|
PT1853266E
(pt)
|
2005-01-10 |
2012-01-20 |
Cortendo Ab Publ |
2s,4r-cetoconazole para o tratamento de diabetes, síndrome metabólica e outras condições
|
|
US20060172012A1
(en)
|
2005-01-28 |
2006-08-03 |
Finley John W |
Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
|
|
US20060189682A1
(en)
|
2005-02-02 |
2006-08-24 |
Payne Joseph E |
Water soluble prodrugs of COX-2 inhibitors
|
|
US20080139604A1
(en)
|
2005-02-17 |
2008-06-12 |
Shaun Fitzpatrick |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
|
US20100254951A1
(en)
|
2005-02-22 |
2010-10-07 |
Mochida Pharmaceutical Co., Ltd. |
Nerve Regeneration Promoting Agent
|
|
EP1861087A4
(en)
|
2005-03-08 |
2010-02-10 |
Reliant Pharmaceuticals Inc |
TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
|
|
US8367725B2
(en)
|
2005-07-08 |
2013-02-05 |
Mochida Pharmaceutical Co., Ltd. |
Composition and/or method for preventing onset and/or recurrence of cardiovascular events
|
|
JP2009515815A
(ja)
|
2005-07-18 |
2009-04-16 |
レリアント ファーマスーティカルズ インコーポレイテッド |
アゼチジノン系コレステロール吸収阻害剤及びオメガ−３脂肪酸を用いた治療、並びにそれらの併用品
|
|
RU2290185C1
(ru)
|
2005-07-26 |
2006-12-27 |
Дмитрий Николаевич Мясников |
Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
|
|
EP1919285A2
(en)
|
2005-07-28 |
2008-05-14 |
Reliant Pharmaceuticals, Inc. |
Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
|
|
ITMI20051560A1
(it)
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
|
US20090227602A1
(en)
|
2005-10-28 |
2009-09-10 |
John Griffin |
Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
|
|
US20070105793A1
(en)
|
2005-11-04 |
2007-05-10 |
Curt Hendrix |
Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
|
|
US20070104779A1
(en)
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
|
JP5113527B2
(ja)
|
2005-11-11 |
2013-01-09 |
持田製薬株式会社 |
ゼリー組成物
|
|
WO2007058523A1
(en)
|
2005-11-17 |
2007-05-24 |
N.V. Nutricia |
Composition with docosapentaenoic acid
|
|
JP2009516681A
(ja)
|
2005-11-21 |
2009-04-23 |
テバ ファーマシューティカル インダストリーズ リミティド |
アトルバスタチン製剤
|
|
EP1968567B1
(en)
|
2005-12-20 |
2014-06-18 |
Cenestra, Llc |
Omega 3 fatty acid formulations
|
|
ATE509624T1
(de)
|
2005-12-23 |
2011-06-15 |
Nutricia Nv |
Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
|
|
US20090182022A1
(en)
|
2006-01-05 |
2009-07-16 |
Reliant Pharmaceuticals |
Treatment of Fatty Liver
|
|
US20070202159A1
(en)
|
2006-02-02 |
2007-08-30 |
Mathur Rajeev S |
Pharmaceutical composition comprising stabilized statin particles
|
|
EP1982710B1
(en)
|
2006-02-07 |
2013-12-18 |
Mochida Pharmaceutical Co., Ltd. |
Composition for prevention of recurrence of stroke
|
|
CN101395170A
(zh)
|
2006-02-14 |
2009-03-25 |
英特塞普特药品公司 |
用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
|
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
|
WO2007128801A1
(en)
|
2006-05-08 |
2007-11-15 |
Novartis Ag |
Combination of organic compounds
|
|
WO2007142118A1
(ja)
|
2006-05-31 |
2007-12-13 |
Mochida Pharmaceutical Co., Ltd. |
多重リスク患者の心血管イベント発症予防用組成物
|
|
CA2656311C
(en)
|
2006-07-05 |
2016-06-21 |
Photonz Corporation Limited |
Ultra pure epa and polar lipids produced in largely heterotrophic culture
|
|
WO2008012329A2
(en)
|
2006-07-28 |
2008-01-31 |
V. Mane Fils |
Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
|
|
US20080085911A1
(en)
|
2006-10-10 |
2008-04-10 |
Reliant Pharmaceuticals, Inc. |
Statin and omega-3 fatty acids for reduction of apo-b levels
|
|
EA018734B1
(ru)
|
2006-10-10 |
2013-10-30 |
Релайэнт Фармасьютикалз, Инк. |
СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
|
|
WO2008088415A1
(en)
|
2006-10-18 |
2008-07-24 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids for reduction of lp-pla2 levels
|
|
US20080125490A1
(en)
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
|
US20080306154A1
(en)
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
|
CA2675836C
(en)
|
2007-01-17 |
2016-10-11 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing or treating thrombus- or embolus-associated disease
|
|
EP2120959A4
(en)
|
2007-01-23 |
2010-05-26 |
Reddys Lab Ltd Dr |
METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
|
|
US20080185198A1
(en)
|
2007-02-02 |
2008-08-07 |
Steven Mark Jones |
Next generation hybrid III parallel/series hybrid system
|
|
CA2672513C
(en)
|
2007-02-15 |
2010-05-25 |
Centre De Recherche Sur Les Biotechnologies Marines |
Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
|
|
US20100055175A1
(en)
|
2007-03-06 |
2010-03-04 |
James Nugent |
Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
|
|
WO2008115529A1
(en)
|
2007-03-20 |
2008-09-25 |
Reliant Pharmaceuticals, Inc. |
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
|
WO2008145170A1
(de)
|
2007-05-31 |
2008-12-04 |
Siemens Aktiengesellschaft |
Verfahren zum konfigurieren einer automatisierungsanlage
|
|
US20080299187A1
(en)
|
2007-06-01 |
2008-12-04 |
Joar Opheim |
Substances for Reducing Occurence of Major Cardiac Events in Humans
|
|
WO2009004999A1
(ja)
|
2007-06-29 |
2009-01-08 |
Takeda Pharmaceutical Company Limited |
シームレスカプセル
|
|
WO2009043834A1
(en)
|
2007-10-01 |
2009-04-09 |
Neurosearch A/S |
Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
|
|
EP2242382B1
(en)
|
2007-12-20 |
2016-11-16 |
Abbott Laboratories |
Stable nutritional powder
|
|
US8361534B2
(en)
|
2007-12-20 |
2013-01-29 |
Abbott Laboratories |
Stable nutritional powder
|
|
CN103705486A
(zh)
|
2008-01-10 |
2014-04-09 |
武田药品工业株式会社 |
胶囊制剂
|
|
US20090182049A1
(en)
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
|
MX2010012482A
(es)
|
2008-05-15 |
2010-12-01 |
Pronova Biopharma Norge As |
Proceso para aceite de kril.
|
|
EP2279734A4
(en)
|
2008-05-20 |
2013-05-01 |
Mochida Pharm Co Ltd |
COMPOSITION FOR PREVENTING A CARDIOVASCULAR EVENT IN HIGH-RISK PATIENTS
|
|
WO2009151125A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
肝障害の診断及び治療
|
|
WO2009151116A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防／改善・治療薬
|
|
US20110105510A1
(en)
|
2008-06-17 |
2011-05-05 |
Hiroshi Ishikawa |
Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
|
|
JP5922868B2
(ja)
|
2008-07-07 |
2016-05-24 |
持田製薬株式会社 |
脂質異常症の改善または治療薬
|
|
JP5924834B2
(ja)
*
|
2008-09-02 |
2016-05-25 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
|
|
JPWO2010038796A1
(ja)
|
2008-09-30 |
2012-03-01 |
持田製薬株式会社 |
Ｃ型肝炎治療剤
|
|
WO2010040012A1
(en)
|
2008-10-01 |
2010-04-08 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
|
WO2010080976A1
(en)
|
2009-01-09 |
2010-07-15 |
Sdg, Inc. (An Ohio Corporation) |
Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
|
|
WO2010083615A1
(en)
|
2009-01-26 |
2010-07-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
DK2596786T3
(da)
|
2009-02-10 |
2020-02-24 |
Amarin Pharmaceuticals Ie Ltd |
Anvendelse af eicosapentaensyreethylester til behandling af hypertriglyceridæmi
|
|
US8241672B2
(en)
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
|
US20120046251A1
(en)
|
2009-04-06 |
2012-02-23 |
The Regents Of The University Of California |
Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
|
|
NZ734905A
(en)
|
2009-04-29 |
2019-05-31 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
HUE034941T2
(en)
*
|
2009-04-29 |
2018-03-28 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition and methods of using same
|
|
CA2762939C
(en)
|
2009-05-22 |
2017-07-18 |
Mochida Phamaceutical Co., Ltd. |
Self-emulsifying composition of .omega.3 fatty acid
|
|
EP3318255B1
(en)
|
2009-06-15 |
2021-03-10 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating stroke in a subject on concomitant statin therapy
|
|
RU2402326C1
(ru)
|
2009-06-22 |
2010-10-27 |
Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) |
Способ коррекции инсулинорезистентности при метаболическом синдроме
|
|
US8557275B2
(en)
|
2009-07-23 |
2013-10-15 |
U.S. Nutraceuticals, LLC |
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
|
|
RU2569063C2
(ru)
|
2009-09-01 |
2015-11-20 |
Катабэйсис Фармасьютикалз, Инк. |
Конъюгаты жирных кислот и ниацина и их применение
|
|
MX2012003555A
(es)
|
2009-09-23 |
2012-07-03 |
Amarin Corp Plc |
Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
|
|
WO2011047259A1
(en)
|
2009-10-16 |
2011-04-21 |
Glaxosmithkline Llc |
Compositions
|
|
CA2777013A1
(en)
|
2009-10-16 |
2011-04-21 |
Mochida Pharmaceutical Co., Ltd. |
Marker associated with non-alcoholic steatohepatitis
|
|
MX337605B
(es)
|
2010-01-08 |
2016-03-10 |
Catabasis Pharmaceuticals Inc |
Derivados de fumarato de acido graso y sus usos.
|
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
|
JP6327497B2
(ja)
|
2010-03-04 |
2018-05-23 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
心血管疾患を処置及び／又は予防するための組成物及び方法
|
|
US8846321B2
(en)
|
2010-03-12 |
2014-09-30 |
President And Fellows Of Harvard College |
Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
|
|
US8663704B2
(en)
|
2010-04-30 |
2014-03-04 |
U.S. Nutraceuticals, LLC |
Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
|
|
US20130156892A1
(en)
|
2010-05-05 |
2013-06-20 |
St. Giles Foods Limited |
Edible compositions and methods of manufacturing edible compositons
|
|
JP5829607B2
(ja)
|
2010-06-30 |
2015-12-09 |
持田製薬株式会社 |
ω３脂肪酸の配合製剤
|
|
AR082930A1
(es)
|
2010-09-08 |
2013-01-16 |
Pronova Biopharma Norge As |
Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
|
|
US20130260403A1
(en)
*
|
2010-10-20 |
2013-10-03 |
GlycoMark Inc. |
Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
|
|
JP5960603B2
(ja)
|
2010-11-09 |
2016-08-02 |
持田製薬株式会社 |
血糖値上昇抑制剤
|
|
WO2012074930A2
(en)
|
2010-11-29 |
2012-06-07 |
Amarin Pharma, Inc. |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
KR101310710B1
(ko)
|
2011-03-23 |
2013-09-27 |
한미약품 주식회사 |
오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
|
|
US20120264824A1
(en)
|
2011-04-15 |
2012-10-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
|
DK3357497T3
(en)
|
2011-04-27 |
2020-11-23 |
Ionis Pharmaceuticals Inc |
Modulation af apolipoprotein ciii (apociii) ekspression
|
|
EP2755646A4
(en)
|
2011-09-15 |
2015-06-10 |
Omthera Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO THROMBIA THERAPY
|
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2792746A4
(en)
|
2011-12-12 |
2015-09-16 |
Nat Cerebral & Cardiovascular Ct |
OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
|
|
US9827219B2
(en)
|
2012-01-06 |
2017-11-28 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
|
|
WO2013148136A1
(en)
|
2012-03-30 |
2013-10-03 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
|
US9492545B2
(en)
|
2012-05-07 |
2016-11-15 |
Omthera Pharmaceuticals Inc. |
Compositions of statins and omega-3 fatty acids
|
|
ES2749201T3
(es)
|
2012-05-15 |
2020-03-19 |
Mochida Pharm Co Ltd |
Agente de prevención primaria de enfermedad cardiovascular para pacientes que tienen altos niveles en sangre de proteína C reactiva de alta sensibilidad
|
|
JP6473414B2
(ja)
|
2012-05-30 |
2019-02-20 |
クラリアント・ファイナンス・（ビーブイアイ）・リミテッド |
向上した泡品質及びより高い粘度を有する、アミノ酸系界面活性剤、ベタイン類及びｎ−メチル−ｎ−アシルグルカミンを含む組成物
|
|
US20140080850A1
(en)
|
2012-06-05 |
2014-03-20 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
|
|
US20130324607A1
(en)
|
2012-06-05 |
2013-12-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypercholesterolemia
|
|
EP2861227A4
(en)
|
2012-06-17 |
2016-01-27 |
Matinas Biopharma Inc |
OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
|
|
US20150157593A1
(en)
|
2012-06-29 |
2015-06-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing ldl-p
|
|
MX392694B
(es)
|
2012-06-29 |
2025-03-24 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
|
|
AU2013284464A1
(en)
|
2012-06-29 |
2015-01-22 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating pediatric metabolic syndrome
|
|
US20140004183A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating cardiovascular disease in statin-tolerant subjects
|
|
US20140005265A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating hypertriglyceridemia
|
|
CN104797249A
(zh)
|
2012-09-28 |
2015-07-22 |
持田制药株式会社 |
用于减少新发糖尿病的组合物
|
|
US9486433B2
(en)
|
2012-10-12 |
2016-11-08 |
Mochida Pharmaceuticals Co. Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
|
EP2719382A1
(en)
|
2012-10-12 |
2014-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US20140213648A1
(en)
|
2012-12-31 |
2014-07-31 |
Amarin Pharmaceuticals Ireland Limited |
Methods of increasing epa blood levels
|
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140221358A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
|
|
US20140221452A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
|
|
US20140221676A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US20140242216A1
(en)
|
2013-02-24 |
2014-08-28 |
Mead Johnson Nutrition Company |
Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
|
|
US20140249220A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
|
|
US20140249225A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
|
US20140249200A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
|
|
US20140249214A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of warfarin and ethyl eicosapentaenoate
|
|
US9661874B2
(en)
|
2013-03-11 |
2017-05-30 |
Mead Johnson Nutrition Company |
Nutritional compositions containing structured fat globules and uses thereof
|
|
US20140255537A1
(en)
|
2013-03-11 |
2014-09-11 |
Mead Johnson Nutrition Company |
Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
|
|
US20140271907A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
|
|
US20140275252A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating traumatic brain injury
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
|
KR20150127599A
(ko)
|
2013-03-15 |
2015-11-17 |
모치다 세이야쿠 가부시키가이샤 |
비알코올성 지방간염을 치료하기 위한 조성물 및 방법
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US20140322314A1
(en)
|
2013-04-29 |
2014-10-30 |
Matinas Biopharma, Inc. |
Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
|
|
US20140357717A1
(en)
|
2013-06-04 |
2014-12-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
WO2015008849A1
(ja)
|
2013-07-18 |
2015-01-22 |
持田製薬株式会社 |
ω３脂肪酸の自己乳化組成物
|
|
CN110840874A
(zh)
|
2013-07-18 |
2020-02-28 |
持田制药株式会社 |
ω-3脂肪酸的自乳化组合物
|
|
US20150045431A1
(en)
|
2013-08-06 |
2015-02-12 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
|
|
US20150051282A1
(en)
|
2013-08-14 |
2015-02-19 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US20150073050A1
(en)
|
2013-09-09 |
2015-03-12 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
|
|
EP3054940B1
(en)
|
2013-10-07 |
2020-09-23 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
WO2015066512A1
(en)
|
2013-10-31 |
2015-05-07 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
PH12016501978B1
(en)
|
2014-04-11 |
2023-07-12 |
Cymabay Therapeutics Inc |
Treatment of nafld and nash
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
CN107405326B
(zh)
|
2015-01-21 |
2021-06-15 |
持田制药株式会社 |
ω3脂肪酸的自乳化组合物
|
|
KR102488648B1
(ko)
|
2015-01-21 |
2023-01-12 |
모치다 세이야쿠 가부시키가이샤 |
ω3 지방산의 자기 유화 조성물
|
|
WO2016140949A1
(en)
|
2015-03-02 |
2016-09-09 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
|
US20170151202A1
(en)
|
2015-09-09 |
2017-06-01 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
LT3275438T
(lt)
|
2016-07-29 |
2021-03-25 |
Kowa Company, Ltd. |
Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US20190054054A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods reducing or preventing oxidation of high density lipoprotein (HDL)
|
|
US20190054058A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of Treating or Preventing Bone Loss
|
|
US20190209506A1
(en)
|
2018-01-09 |
2019-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
US20190275057A1
(en)
|
2018-03-06 |
2019-09-12 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
|
|
MX2021001906A
(es)
|
2018-08-17 |
2021-04-28 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir la necesidad de revascularizacion arterial periferica en un sujeto tratado con estatinas.
|
|
JP7020756B2
(ja)
|
2018-09-24 |
2022-02-16 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
対象の心血管イベントのリスクを低減する方法
|